Condition
Recurrent Non-small Cell Lung Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 88 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung CancerNCT02889666 · 2008-01-01
RECRUITINGA Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17
COMPLETEDCombination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung CancerNCT02845856 · 2016-07-01
COMPLETEDSafety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung CancerNCT02655913 · 2015-12-01
COMPLETEDHypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for SurgeryNCT02262325 · 2015-06-08
COMPLETEDGenetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerNCT02132884 · 2015-03-01
TERMINATEDPalliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family CaregiversNCT02243748 · 2015-02-05
COMPLETEDStereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung CancerNCT02250378 · 2014-10-01
WITHDRAWNComprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung CancerNCT02178163 · 2014-08-01
ACTIVE_NOT_RECRUITINGRadiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung CancerNCT01958372 · 2014-08-01
COMPLETEDS1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After CrizotinibNCT02134912 · 2014-08-01
TERMINATEDDiffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung CancerNCT02059889 · 2014-07-01
WITHDRAWNGene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung CancerNCT02145078 · 2014-06-01
TERMINATEDPemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibNCT01928160 · 2014-06-01
WITHDRAWNPemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung CancerNCT01784640 · 2014-01-31
COMPLETEDNintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy RegimensNCT01948141 · 2014-01-30
COMPLETEDDocetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung CancerNCT01824901 · 2014-01-15
COMPLETEDImpacts of Exercise on Prognostic Biomarkers in Lung Cancer PatientsNCT01999881 · 2013-12-01
COMPLETEDPaclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV InfectionNCT01249443 · 2013-11-01
TERMINATEDPulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing ChemoradiationNCT02017925 · 2013-10-01
WITHDRAWNStudy of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive BiomarkersNCT01935336 · 2013-09-24
COMPLETEDErlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung CancerNCT01839955 · 2013-09-01
COMPLETEDINC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung CancerNCT01911507 · 2013-08-27
COMPLETEDAuranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung CancerNCT02126527 · 2013-08-01
WITHDRAWNPI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung CancerNCT01723800 · 2013-07-01
COMPLETEDStereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung CancerNCT01781741 · 2013-03-06
COMPLETED18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyNCT01806675 · 2013-03-04
COMPLETEDCognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their CaregiversNCT01729689 · 2012-11-01
COMPLETEDLow-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung CancerNCT01707823 · 2012-10-01
TERMINATEDIR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung TumorsNCT01746810 · 2012-07-01
TERMINATEDModulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase IINCT01649947 · 2011-12-23
COMPLETEDRadiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01411098 · 2011-10-01
TERMINATEDSirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung CancerNCT01383668 · 2011-06-01
WITHDRAWNImage-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By SurgeryNCT01345851 · 2011-03-23
ACTIVE_NOT_RECRUITINGCryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the BodyNCT01325753 · 2011-03-01
WITHDRAWNRO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line ChemotherapyNCT01193868 · 2010-09-01
TERMINATEDTemsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsNCT01155258 · 2010-06-01
COMPLETEDFrailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung CancerNCT01026467 · 2010-01-01
COMPLETEDCarboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung CancerNCT00976677 · 2010-01-01
TERMINATEDCarboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung CancerNCT00986674 · 2009-09-01
COMPLETEDErlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00778167 · 2008-10-01
COMPLETEDAZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination ChemotherapyNCT00638937 · 2008-02-01
COMPLETEDErlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung CancerNCT00499655 · 2007-11-01
COMPLETEDDocetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT01557959 · 2007-07-01
COMPLETEDVorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung CancerNCT00481078 · 2007-05-01
COMPLETEDDasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00459342 · 2007-03-01
COMPLETEDErlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerNCT00397384 · 2007-01-01
COMPLETEDE7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00400829 · 2006-11-01
COMPLETEDAZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung CancerNCT00410904 · 2006-10-01
COMPLETEDS0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung CancerNCT00368992 · 2006-08-01
COMPLETEDDocetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung CancerNCT00362882 · 2006-07-01
COMPLETEDAZD2171 in Treating Patients With Recurrent Small Cell Lung CancerNCT00245063 · 2006-03-01
COMPLETEDImatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00408460 · 2006-02-01
COMPLETEDDocetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerNCT00118183 · 2005-07-01
COMPLETEDBortezomib in Treating Patients With Stage IIIB or Stage IV Lung CancerNCT00118144 · 2005-06-01
COMPLETEDSuberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00138203 · 2005-06-01
COMPLETEDErlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01
COMPLETEDSorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00098540 · 2004-12-01
COMPLETEDEverolimus and Vatalanib in Treating Patients With Advanced Solid TumorsNCT00655655 · 2004-12-01
COMPLETEDBortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung CancerNCT00093756 · 2004-09-01
COMPLETEDCommon interventions
laboratory biomarker analysisOTHER42carboplatinDRUG16pharmacological studyOTHER16erlotinib hydrochlorideDRUG15paclitaxelDRUG13DocetaxelDRUG9cisplatinDRUG8bortezomibDRUG7pemetrexed disodiumDRUG7gemcitabine hydrochlorideDRUG5quality-of-life assessmentPROCEDURE5bevacizumabBIOLOGICAL4cetuximabBIOLOGICAL4questionnaire administrationOTHER43-dimensional conformal radiation therapyRADIATION3celecoxibDRUG3etoposideDRUG3pharmacogenomic studiesOTHER3quality-of-life assessmentOTHER3vorinostatDRUG3cediranib maleateDRUG2CetuximabDRUG2cixutumumabBIOLOGICAL2cytology specimen collection procedureOTHER2diagnostic laboratory biomarker analysisOTHER2
Leading sponsors
National Cancer Institute (NCI)
45
Barbara Ann Karmanos Cancer Institute
3
City of Hope Medical Center
3
Mayo Clinic
3
Roswell Park Cancer Institute
3
University of Washington
3
Wake Forest University Health Sciences
3
Jonsson Comprehensive Cancer Center
2
Ohio State University Comprehensive Cancer Center
2
University of Southern California
2
Vanderbilt-Ingram Cancer Center
2
AIDS Malignancy Consortium
1
Bristol-Myers Squibb
1
Clifford Hospital, Guangzhou, China
1
ECOG-ACRIN Cancer Research Group
1
Trial status mix
COMPLETED65
TERMINATED13
WITHDRAWN7
ACTIVE_NOT_RECRUITING2
RECRUITING1
Phase mix
PHASE245
PHASE135
NA14
EARLY_PHASE12
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.